IL-23R:IL-23A[Biotinylated] Inhibitor Screening Assay Kit
The IL-23R:IL-23A[Biotynilated] Inhibitor Screening Assay Kit is designed to measure the binding of IL-23R (interleukin 23 receptor) to IL-23A (IL-23 subunit alpha) for screening and profiling applications. The IL-23R:IL-23A[Biotinylated] Inhibitor Screening Assay Kit comes in a convenient 96-well format, with enough recombinant purified biotinylated IL-23A, IL-23R, blocking and assay buffer and detection reagents for 100 enzyme reactions.
Need us to run inhibitor screens or profile your compounds against IL-23RA:IL-23A[Biotin]? Check out our Immunotherapy Biochemical Screening Services.
- 1x PBS (phosphate buffer saline) Buffer
- Luminometer or microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
| Catalog # | Name | Amount | Storage |
| IL-23A[Biotin]* | 2 µg | -80°C | |
| IL-23R | 20 µg | -80°C | |
| 79311 | 3x Immuno Buffer 1 | 50 ml | -20°C |
| 79728 | Blocking buffer 2 | 50 ml | +4°C |
| 79742 | Streptavidin-HRP | 10 µl | +4°C |
| 79670 | ELISA ECL Substrate A (translucent bottle) | 6 ml | Room Temp |
| ELISA ECL Substrate B (brown bottle) | 6 ml | Room Temp | |
| 79699 | White 96-well microplate | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
IL-23 (interleukin 23) is a cytokine involved in inflammation. It is composed of two subunits, IL-12B (or IL-12p40) and IL-23A (or IL-23 p19) and binds to the IL-23 receptor. It supports Th17 T cell maintenance, expansion and cytokine release, NK cell IFNγ (interferon γ) secretion and increased ADCC (antibody-dependent cellular cytotoxicity) and CD4+ T cell proliferation. IL-23 is produced and secreted by activated dendritic cells, macrophages, B cells and γδ T cells. Excessive production of this cytokine can lead to autoimmune disorders, such as psoriasis, and even cancer. Ustekinumab (sold under the brand name STELARA®) and guselkumab (sold under the brand name Tremfya®) are two commercial monoclonal antibodies targeting IL-23, designed for the treatment of Crohn’s disease, ulcerative colitis, plaque and arthritic psoriasis. The success of these two drugs indicates the relevance of this cytokine in human health and disease, making it a valuable therapeutic target.
McKenzie B.S., et al. 2006 Trends in Immunology 27(1): 17-23.
Iwakura, Y. and Harumichi I. 2006 The Journal of clinical investigation 116(5): 1218-1222.
Fragoulis G. and Siebert S., 2022 Musculoskeletal Care 20 (suppl 1): S12-S21.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.